Sanofi ROA 2012-2026 | SNY
Current and historical return on assets (ROA) values for Sanofi (SNY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Sanofi ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $8.76B | $146.72B | 5.97% |
| 2025-12-31 | $8.84B | $144.00B | 6.14% |
| 2025-09-30 | $10.21B | $144.06B | 7.09% |
| 2025-06-30 | $10.03B | $106.13B | 9.45% |
| 2025-03-31 | $6.76B | $105.60B | 6.40% |
| 2024-12-31 | $6.02B | $70.86B | 8.49% |
| 2024-09-30 | $4.91B | $69.15B | 7.11% |
| 2024-06-30 | $4.57B | $69.15B | 6.60% |
| 2024-03-31 | $4.93B | $68.39B | 7.21% |
| 2023-12-31 | $5.84B | $68.39B | 8.55% |
| 2023-09-30 | $9.68B | $67.55B | 14.33% |
| 2023-06-30 | $9.02B | $67.55B | 13.35% |
| 2023-03-31 | $8.71B | $65.79B | 13.23% |
| 2022-12-31 | $8.82B | $65.79B | 13.41% |
| 2022-09-30 | $8.33B | $32.41B | 25.69% |
| 2022-03-31 | $6.88B | $33.83B | 20.32% |
| 2021-09-30 | $6.90B | $33.83B | 20.40% |
| 2021-03-31 | $7.99B | 0 | 0.00% |
| 2020-09-30 | $7.39B | 0 | 0.00% |
| 2020-03-31 | $6.36B | 0 | 0.00% |
| 2019-09-30 | $4.98B | $28.21B | 17.65% |
| 2019-03-31 | $4.86B | $28.21B | 17.22% |
| 2018-03-31 | $4.71B | $56.23B | 8.37% |
| 2017-12-31 | $9.53B | $56.23B | 16.96% |
| 2017-09-30 | $9.90B | $56.98B | 17.37% |
| 2017-06-30 | $9.92B | $56.98B | 17.41% |
| 2017-03-31 | $10.09B | $56.95B | 17.71% |
| 2016-12-31 | $5.21B | $56.95B | 9.15% |
| 2016-09-30 | $6.19B | $27.99B | 22.10% |
| 2016-06-30 | $5.76B | $55.07B | 10.46% |
| 2016-03-31 | $5.52B | $58.19B | 9.48% |
| 2015-09-30 | $4.90B | $89.86B | 5.45% |
| 2015-06-30 | $4.59B | $122.54B | 3.75% |
| 2014-06-30 | $5.57B | $95.46B | 5.83% |
| 2013-06-30 | $6.39B | $99.23B | 6.44% |
| 2012-06-30 | $8.61B | $67.57B | 12.74% |
| 2012-03-31 | $8.56B | $70.70B | 12.10% |
| 2011-12-31 | $9.33B | $70.70B | 13.20% |
| 2011-09-30 | $8.04B | $64.13B | 12.53% |
| 2011-06-30 | $7.45B | $64.13B | 11.62% |
| 2011-03-31 | $8.22B | $55.82B | 14.73% |
| 2010-12-31 | $8.24B | $55.82B | 14.76% |
| 2010-09-30 | $9.30B | $55.42B | 16.78% |
| 2010-06-30 | $10.37B | $55.42B | 18.71% |
| 2010-03-31 | $11.38B | $54.05B | 21.05% |
| 2009-12-31 | $10.99B | $54.05B | 20.34% |
| 2009-09-30 | $9.57B | $52.62B | 18.20% |
| 2009-06-30 | $8.26B | $52.62B | 15.69% |
| 2009-03-31 | $7.76B | $52.86B | 14.67% |
| 2008-12-31 | $7.76B | $52.86B | 14.69% |
| 2008-09-30 | $9.72B | $51.03B | 19.04% |
| 2008-06-30 | $10.42B | $51.03B | 20.42% |
| 2008-03-31 | $9.21B | $49.95B | 18.44% |
| 2007-12-31 | $8.40B | $49.95B | 16.82% |
| 2007-09-30 | $6.95B | $49.73B | 13.97% |
| 2007-06-30 | $6.45B | $49.73B | 12.98% |
| 2007-03-31 | $7.18B | $50.03B | 14.36% |
| 2006-12-31 | $6.99B | $50.03B | 13.97% |
| 2006-09-30 | $6.79B | $52.59B | 12.91% |
| 2006-06-30 | $6.95B | $52.59B | 13.22% |
| 2006-03-31 | $6.66B | $55.13B | 12.08% |
| 2005-12-31 | $5.54B | $55.13B | 10.05% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |